Medicenna Therapeutics Corp. (MDNA)
Stock Price: $4.38 USD
-0.02 (-0.45%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $4.51 +0.13 (2.97%) Jan 21, 7:59 PM
| Market Cap | 219.70M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 48.85M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $4.38 |
| Previous Close | $4.40 |
| Change ($) | -0.02 |
| Change (%) | -0.45% |
| Day's Open | 4.56 |
| Day's Range | 4.34 - 4.62 |
| Day's Volume | 470,250 |
| 52-Week Range | 3.55 - 5.97 |
News
There are no news available yet.
About MDNA
Medicenna Therapeutics, a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat... [Read more...]
| Industry Biotechnology | |
| CEO Dr. Fahar Merchant | Employees 7 |
| Stock Exchange NASDAQ | Ticker Symbol MDNA |